Karyopharm Therapeutics Inc.
KPTI
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Karyopharm Therapeutics is a biopharmaceutical company whose drug development pipeline relies on animal testing. The company’s lead oncology drug, selinexor, was approved by the FDA based on preclinical studies conducted in animal models. This reliance on animal testing is central to its business model for developing cancer therapeutics.
A 2022 report by the Physicians Committee for Responsible Medicine documented 37 animal welfare violations at research facilities between March 2018 and April 2021 involving companies developing neural device technology. While this report does not cite Karyopharm directly, it highlights the broader industry context of animal welfare incidents in biomedical research. Karyopharm operates within this sector, where animal testing is a standard, required component of the regulatory pathway for drug approval.
The company has not published a corporate policy committing to the development, validation, and adoption of animal-free testing methods. Its research and development activities continue to depend on animal models.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.